BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04139-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Jee Soo Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Oncolytic Virotherapy, Ubiquitin Thiolesterase, Kidney Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korean Urological Oncology Society, Patient-Centered Clinical Research Coordinating Center, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Background
The therapeutic efficacy of oncolytic vaccinia virus (JX-594) has been demonstrated in metastatic clear cell renal cell carcinoma (ccRCC); however, only selected patients respond, and there are no predictive biomarkers for therapeutic response. We aimed to identify predictive biomarkers for JX-594 treatment and elucidate the underlying mechanisms.
Methods
Four cell line-derived xenograft (CDX) models were developed using representative ccRCC cell lines harboring common mutations. Tumors were subcutaneously implanted into the right flank of BALB/c nude mice. Mice were treated with vehicle or JX-594 via intratumoral injection on days 0, 3, and 6, and tumor growth was evaluated. Therapeutic efficacies of JX-594 and a STING agonist were compared in the BAP1-mutant (769-P) CDX model.
Results
All four CDX models showed significant tumor shrinkage following JX-594 treatment versus control. JX-594 exhibited greater efficacy than the STING agonist in BAP1-deficient xenografts. The BAP1 mutation was associated with rapid tumor progression and a stronger response to JX-594. JX-594 induced IFN-β expression through IRF7-dependent signaling in BAP1-deficient cells, bypassing impaired STING–IRF3 signaling.
Conclusions
We identified BAP1 as a potential predictive biomarker for JX-594 treatment and explored its underlying mechanisms. However, given that the study used immunodeficient models, the findings reflect tumor-intrinsic interferon responses and require further validation in immunocompetent models to assess immune microenvironment modulation and clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
- Department of Urology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republic of Korea.
- Research Center, SillaJen, Inc., Seoul, Republic of Korea.
- Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. uroham@yuhs.ac.
Förderung
- Korean Urological Oncology Society
- Patient-Centered Clinical Research Coordinating Center
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Yonsei University College of Medicine
Zitieren
APA
Park, J. S., Jang, W. S., Lee, M. E., Kim, J., Oh, K., Lee, N., & Ham, W. S. (2025). BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04139-4
Vancouver
Park JS, Jang WS, Lee ME, Kim J, Oh K, Lee N, et al. BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04139-4
BibTeX
@article{Park2025,
author = {Park, Jee Soo and Jang, Won Sik and Lee, Myung Eun and Kim, Jongchan and Oh, Keunhee and Lee, Namhee and Ham, Won Sik},
title = {BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04139-4}
}
EUVIMED